{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:50:53Z","timestamp":1788969053786,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["431232613"],"award-info":[{"award-number":["431232613"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["CRC 1449"],"award-info":[{"award-number":["CRC 1449"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","award":["01GL2401B"],"award-info":[{"award-number":["01GL2401B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","award":["031L0220B"],"award-info":[{"award-number":["031L0220B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","award":["82DZL009C1"],"award-info":[{"award-number":["82DZL009C1"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research Bonn Office","doi-asserted-by":"publisher","award":["01GL2401A"],"award-info":[{"award-number":["01GL2401A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Systems"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cels.2026.101569","type":"journal-article","created":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:00:20Z","timestamp":1775055620000},"page":"101569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic effects of cystic fibrosis transmembrane conductance regulator modulators on the plasma and serum proteome"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0437-1049","authenticated-orcid":false,"given":"Kerstin","family":"Fentker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieluise","family":"Kirchner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Ziehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Niquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Duerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Schaupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jobst","family":"Roehmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Thee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"H\u00e4mmerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"Sommerburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirjam","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Y.","family":"Graeber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Mall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-528X","authenticated-orcid":false,"given":"Philipp","family":"Mertins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cels.2026.101569_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-024-00538-6","article-title":"Cystic fibrosis","volume":"10","author":"Mall","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.cels.2026.101569_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jcf.2013.12.003","article-title":"The relative frequency of CFTR mutation classes in European patients with cystic fibrosis","volume":"13","author":"De Boeck","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.cels.2026.101569_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ph16030410","article-title":"Elexacaftor-Tezacaftor-Ivacaftor: A Life-Changing Triple Combination of CFTR Modulator Drugs for Cystic Fibrosis","volume":"16","author":"Bacalhau","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.cels.2026.101569_bib4","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMra2216474","article-title":"Cystic Fibrosis","volume":"389","author":"Grasemann","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cels.2026.101569_bib5","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","article-title":"The future of cystic fibrosis care: a global perspective","volume":"8","author":"Bell","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cels.2026.101569_bib6","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1378\/chest.12-0628","article-title":"Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa","volume":"142","author":"Ratjen","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.cels.2026.101569_bib7","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2014.09.005","article-title":"Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation","volume":"13","author":"De Boeck","year":"2014","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.cels.2026.101569_bib8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1513\/AnnalsATS.202002-144OC","article-title":"Clinical Effectiveness of Lumacaftor\/Ivacaftor in Patients with Cystic Fibrosis Homozygous for F508del-CFTR. A Clinical Trial","volume":"18","author":"Sagel","year":"2021","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.cels.2026.101569_bib9","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1164\/rccm.201710-1983OC","article-title":"Effects of Lumacaftor-Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis","volume":"197","author":"Graeber","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cels.2026.101569_bib10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/thoraxjnl-2011-200393","article-title":"Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation","volume":"67","author":"Clancy","year":"2012","journal-title":"Thorax"},{"key":"10.1016\/j.cels.2026.101569_bib11","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cels.2026.101569_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.cels.2026.101569_bib13","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1164\/rccm.202204-0734OC","article-title":"A Phase 3, Open-Label Study of Lumacaftor\/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR","volume":"206","author":"Rayment","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cels.2026.101569_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cels.2026.101569_bib15","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cels.2026.101569_bib16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1164\/rccm.202008-3176LE","article-title":"Safety and Efficacy of Elexacaftor\/Tezacaftor\/Ivacaftor for 24 Weeks or Longer in People with Cystic Fibrosis and One or More F508del Alleles: Interim Results of an Open-Label Phase 3 Clinical Trial","volume":"203","author":"Griese","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cels.2026.101569_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1164\/rccm.202201-0219OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"206","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cels.2026.101569_bib18","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.jcf.2022.12.012","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy in children with cystic fibrosis - a comprehensive assessment using lung clearance index, spirometry, and functional and structural lung MRI","volume":"22","author":"Streibel","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.cels.2026.101569_bib19","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00004-2024","article-title":"Impact of elexacaftor\/tezacaftor\/ivacaftor therapy on lung clearance index and magnetic resonance imaging in children with cystic fibrosis and one or two F508del alleles","volume":"64","author":"Stahl","year":"2024","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cels.2026.101569_bib20","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02153-2022","article-title":"Longitudinal Effects of Elexacaftor\/Tezacaftor\/Ivacaftor on Sputum Viscoelastic Properties, Airway Infection and Inflammation in Patients with Cystic Fibrosis","volume":"62","author":"Schaupp","year":"2023","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cels.2026.101569_bib21","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jcf.2023.10.019","article-title":"Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis","volume":"23","author":"Maher","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.cels.2026.101569_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1136\/thorax-2022-219943","article-title":"Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis","volume":"78","author":"Casey","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.cels.2026.101569_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1179208","article-title":"Effects of elexacaftor\/tezacaftor\/ivacaftor therapy on mental health of patients with cystic fibrosis","volume":"14","author":"Piehler","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cels.2026.101569_bib24","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/S0140-6736(23)01608-2","article-title":"The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches","volume":"402","author":"Graeber","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cels.2026.101569_bib25","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cels.2016.02.015","article-title":"Plasma Proteome Profiling to Assess Human Health and Disease","volume":"2","author":"Geyer","year":"2016","journal-title":"Cell Syst."},{"key":"10.1016\/j.cels.2026.101569_bib26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cels.2020.05.012","article-title":"Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection","volume":"11","author":"Messner","year":"2020","journal-title":"Cell Syst."},{"key":"10.1016\/j.cels.2026.101569_bib27","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jcf.2022.03.012","article-title":"Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D","volume":"21","author":"Hoppe","year":"2022","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.cels.2026.101569_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/cells11121938","article-title":"CFTR Rescue by Lumacaftor (VX-809) Induces an Extensive Reorganization of Mitochondria in the Cystic Fibrosis Bronchial Epithelium","volume":"11","author":"Braccia","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.cels.2026.101569_bib29","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jcf.2023.02.005","article-title":"Investigating serum extracellular vesicles in Cystic Fibrosis","volume":"22","author":"Trappe","year":"2023","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.cels.2026.101569_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22083928","article-title":"Identification of Potential Leukocyte Biomarkers Related to Drug Recovery of CFTR: Clinical Applications in Cystic Fibrosis","volume":"22","author":"Pedrazzi","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cels.2026.101569_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.01219","article-title":"CFTR Modulator Therapy Enhances Peripheral Blood Monocyte Contributions to Immune Responses in People With Cystic Fibrosis","volume":"11","author":"Hisert","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.cels.2026.101569_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/thoraxjnl-2014-206710","article-title":"Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry","volume":"71","author":"Quon","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.cels.2026.101569_bib33","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jcf.2017.10.013","article-title":"Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations","volume":"17","author":"Roberts","year":"2018","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.cels.2026.101569_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.microb.2023.100023","article-title":"Integrating airway microbiome and blood proteomics data to identify multi-omic networks associated with response to pulmonary infection","volume":"1","author":"Graham","year":"2023","journal-title":"Microbe"},{"key":"10.1016\/j.cels.2026.101569_bib35","doi-asserted-by":"crossref","first-page":"17126","DOI":"10.1038\/s41598-019-53759-1","article-title":"Identification of novel blood biomarkers of treatment response in cystic fibrosis pulmonary exacerbations by label-free quantitative proteomics","volume":"9","author":"Dong","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cels.2026.101569_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197415","article-title":"Serum-Based Proteomics Profiling in Adult Patients with Cystic Fibrosis","volume":"21","author":"Benabdelkamel","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cels.2026.101569_bib37","doi-asserted-by":"crossref","DOI":"10.1002\/prca.201600147","article-title":"Proteomic profiling identifies novel circulating markers associated with bronchiectasis in cystic fibrosis","volume":"11","author":"DeBoer","year":"2017","journal-title":"Proteomics Clin. Appl."},{"key":"10.1016\/j.cels.2026.101569_bib38","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1034\/j.1399-3003.1999.14b32.x","article-title":"Cystic fibrosis: inflammatory response to infection with Burkholderia cepacia and Pseudomonas aeruginosa","volume":"14","author":"Hendry","year":"1999","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cels.2026.101569_bib39","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jcf.2019.12.007","article-title":"Utilizing centralized biorepository samples for biomarkers of cystic fibrosis lung disease severity","volume":"19","author":"Sagel","year":"2020","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.cels.2026.101569_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089341","article-title":"Plasma sCD14 as a biomarker to predict pulmonary exacerbations in cystic fibrosis","volume":"9","author":"Quon","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cels.2026.101569_bib41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.cca.2020.05.015","article-title":"Laboratory biomarkers for lung disease severity and progression in cystic fibrosis","volume":"508","author":"Bene","year":"2020","journal-title":"Clin. Chim. Acta; Int. J. Clin. Chem."},{"key":"10.1016\/j.cels.2026.101569_bib42","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jprot.2010.10.001","article-title":"Serum proteomics signature of cystic fibrosis patients: a complementary 2-DE and LC-MS\/MS approach","volume":"74","author":"Charro","year":"2011","journal-title":"J. Proteom."},{"key":"10.1016\/j.cels.2026.101569_bib43","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcf.2020.06.017","article-title":"Evaluation of airway and circulating inflammatory biomarkers for cystic fibrosis drug development","volume":"20","author":"Jain","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.cels.2026.101569_bib44","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jcf.2010.01.005","article-title":"Sputum and serum calprotectin are useful biomarkers during CF exacerbation","volume":"9","author":"Gray","year":"2010","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.cels.2026.101569_bib45","article-title":"Serum Fibrinogen as a Biomarker for Disease Severity and Exacerbation in Patients with Non-Cystic Fibrosis Bronchiectasis","volume":"11","author":"Lee","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.cels.2026.101569_bib46","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1164\/rccm.202110-2249OC","article-title":"Effects of Elexacaftor\/Tezacaftor\/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles","volume":"205","author":"Graeber","year":"2022","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cels.2026.101569_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101436","article-title":"Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: A systematic review and meta-analysis","volume":"32","author":"Causer","year":"2020","journal-title":"Redox Biol."},{"key":"10.1016\/j.cels.2026.101569_bib48","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1164\/ajrccm.157.6.9704086","article-title":"Circulating immunoreactive interleukin-6 in cystic fibrosis","volume":"157","author":"Nixon","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cels.2026.101569_bib49","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1002\/iid3.426","article-title":"Immunoglobulin G: A useful outcome marker in the follow-up of cystic fibrosis patients?","volume":"9","author":"Hanssens","year":"2021","journal-title":"Immun. Inflam. Dis."},{"key":"10.1016\/j.cels.2026.101569_bib50","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/17512433.2017.1378094","article-title":"Lumacaftor\/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation","volume":"10","author":"Bulloch","year":"2017","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.cels.2026.101569_bib51","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1164\/rccm.202210-1938LE","article-title":"Moving the Dial on Airway Inflammation in Response to Trikafta in Adolescents with Cystic Fibrosis","volume":"207","author":"Lepissier","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cels.2026.101569_bib52","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/cts.12428","article-title":"Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis","volume":"10","author":"Elborn","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.cels.2026.101569_bib53","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jcf.2021.08.007","article-title":"Empire-CF study: A phase 2 clinical trial of leukotriene A4 hydrolase inhibitor acebilustat in adult subjects with cystic fibrosis","volume":"20","author":"Elborn","year":"2021","journal-title":"J. Cyst. Fibros."},{"key":"10.1016\/j.cels.2026.101569_bib54","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1126\/science.1190594","article-title":"A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation","volume":"330","author":"Snelgrove","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.cels.2026.101569_bib55","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.dld.2014.06.011","article-title":"Digestive system dysfunction in cystic fibrosis: challenges for nutrition therapy","volume":"46","author":"Li","year":"2014","journal-title":"Dig. Liver Dis."},{"key":"10.1016\/j.cels.2026.101569_bib56","doi-asserted-by":"crossref","first-page":"G609","DOI":"10.1152\/ajpgi.00332.2005","article-title":"Abnormal intracellular lipid processing contributes to fat malabsorption in cystic fibrosis patients","volume":"290","author":"Peretti","year":"2006","journal-title":"Am. J. Physiol., Gastrointest. Liver Physiol."},{"key":"10.1016\/j.cels.2026.101569_bib57","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2337\/db16-0286","article-title":"Hepatocytes Are the Principal Source of Circulating RBP4 in Mice","volume":"66","author":"Thompson","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.cels.2026.101569_bib58","doi-asserted-by":"crossref","first-page":"15269","DOI":"10.1074\/jbc.RA118.004294","article-title":"Liver-secreted RBP4 does not impair glucose homeostasis in mice","volume":"293","author":"Fedders","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cels.2026.101569_bib59","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41586-023-06802-1","article-title":"Organ aging signatures in the plasma proteome track health and disease","volume":"624","author":"Oh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.cels.2026.101569_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.659977","article-title":"Biological Functions of RBP4 and Its Relevance for Human Diseases","volume":"12","author":"Steinhoff","year":"2021","journal-title":"Front. Physiol."},{"key":"10.1016\/j.cels.2026.101569_bib61","doi-asserted-by":"crossref","DOI":"10.1186\/1476-9255-10-31","article-title":"Low Serum retinol-binding protein-4 levels in acute exacerbations of chronic obstructive pulmonary disease at intensive care unit admission is a predictor of mortality in elderly patients","volume":"10","author":"Jin","year":"2013","journal-title":"J. Inflamm. (Lond)"},{"key":"10.1016\/j.cels.2026.101569_bib62","article-title":"Identification of CFH and FHL2 as biomarkers for idiopathic pulmonary fibrosis","volume":"11","author":"Liu","year":"2024","journal-title":"Front. Med. (Lausanne)"},{"key":"10.1016\/j.cels.2026.101569_bib63","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-64759-x","article-title":"Label-free plasma proteomics identifies haptoglobin-related protein as candidate marker of idiopathic pulmonary fibrosis and dysregulation of complement and oxidative pathways","volume":"10","author":"Saraswat","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cels.2026.101569_bib64","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ccr.2011.08.007","article-title":"Lung cancer signatures in plasma based on proteome profiling of mouse tumor models","volume":"20","author":"Taguchi","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cels.2026.101569_bib65","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2015.61.7779","article-title":"Diacetylspermine Is a Novel Prediagnostic Serum Biomarker for Non-Small-Cell Lung Cancer and Has Additive Performance With Pro-Surfactant Protein B","volume":"33","author":"Wikoff","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cels.2026.101569_bib66","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2013.50.6105","article-title":"Pro-surfactant protein B as a biomarker for lung cancer prediction","volume":"31","author":"Sin","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cels.2026.101569_bib67","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1164\/ajrccm.156.4.9603061","article-title":"Surfactant proteins-A and -B are elevated in plasma of patients with acute respiratory failure","volume":"156","author":"Doyle","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.cels.2026.101569_bib68","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1183\/09031936.02.02042001","article-title":"Serum levels of CC16, SP-A and SP-B reflect tobacco-smoke exposure in asymptomatic subjects","volume":"20","author":"Robin","year":"2002","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cels.2026.101569_bib69","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00100-2019","article-title":"Vascular permeability in the fibrotic lung","volume":"56","author":"Probst","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.cels.2026.101569_bib70","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083881","article-title":"Budesonide\/formoterol enhances the expression of pro Surfactant Protein-B in lungs of COPD patients","volume":"8","author":"Um","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cels.2026.101569_bib80","doi-asserted-by":"crossref","first-page":"D543","DOI":"10.1093\/nar\/gkab1038","article-title":"The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences","volume":"50","author":"Perez-Riverol","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cels.2026.101569_bib72","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1021\/ac026117i","article-title":"Stop and go extraction tips for matrix-assisted laser desorption\/ionization, nanoelectrospray, and LC\/MS sample pretreatment in proteomics","volume":"75","author":"Rappsilber","year":"2003","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cels.2026.101569_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28508-0","article-title":"Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection","volume":"13","author":"Pekayvaz","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.cels.2026.101569_bib79","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1074\/mcp.M114.046813","article-title":"Multiplexed, Quantitative Workflow for Sensitive Biomarker Discovery in Plasma Yields Novel Candidates for Early Myocardial Injury","volume":"14","author":"Keshishian","year":"2015","journal-title":"Mol. Cell Proteomics"},{"key":"10.1016\/j.cels.2026.101569_bib74","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41592-018-0003-5","article-title":"BoxCar acquisition method enables single-shot proteomics at a depth of 10,000 proteins in 100 minutes","volume":"15","author":"Meier","year":"2018","journal-title":"Nat. Methods"},{"key":"10.1016\/j.cels.2026.101569_bib75","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1021\/acs.jproteome.2c00145","article-title":"Protein Contaminants Matter: Building Universal Protein Contaminant Libraries for DDA and DIA Proteomics","volume":"21","author":"Frankenfield","year":"2022","journal-title":"J. Proteome Res."},{"key":"10.1016\/j.cels.2026.101569_bib71","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201411","article-title":"Disease- and sex-specific differences in patients with heart valve disease: a proteome study","volume":"6","author":"Nordmeyer","year":"2023","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.cels.2026.101569_bib76","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1038\/nprot.2016.136","article-title":"The MaxQuant computational platform for mass spectrometry-based shotgun proteomics","volume":"11","author":"Tyanova","year":"2016","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.cels.2026.101569_bib77","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.cels.2026.101569_bib78","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA."}],"container-title":["Cell Systems"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405471226000517?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405471226000517?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T15:21:44Z","timestamp":1779290504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405471226000517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":80,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2405471226000517"],"URL":"https:\/\/doi.org\/10.1016\/j.cels.2026.101569","relation":{},"ISSN":["2405-4712"],"issn-type":[{"value":"2405-4712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic effects of cystic fibrosis transmembrane conductance regulator modulators on the plasma and serum proteome","name":"articletitle","label":"Article Title"},{"value":"Cell Systems","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cels.2026.101569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101569"}}